New Frontiers in Monoclonal Antibodies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

New Frontiers in Monoclonal Antibodies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma. Approximately 60% of patients are cured with R-CHOP as a frontline treatment, while the remaining patients experience primary refractory or relapsed disease (R/R). The prognosis for R/R DLBCL patients who are neither eligi...

Full description

Bibliographic Details
Main Authors: Mattia Schipani, Giulia Maria Rivolta, Gloria Margiotta-Casaluci, Abdurraouf Mokhtar Mahmoud, Wael Al Essa, Gianluca Gaidano, Riccardo Bruna
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Cancers
Subjects:
diffuse large B-cell lymphoma
monoclonal antibodies
target therapy
bispecific antibodies
antibody-dependent cellular cytotoxicity
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/2072-6694/16/1/187

Internet

https://www.mdpi.com/2072-6694/16/1/187

Similar Items